1|0|Public
50|$|<b>Priliximab</b> (cMT 412) is a human-mouse {{chimeric}} anti-CD4 monoclonal antibody. It {{has been}} tested on patients with Crohn's disease and multiple sclerosis but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.|$|E

